PYXS MICVO shows strong efficacy and safety in advanced head/neck cancer
MICVO demonstrated a 36% response rate and 94% disease control in heavily pretreated head and neck cancer patients, with rapid, deep, durable responses and a manageable safety profile. Consistent subgroup efficacy supports global phase III plans.
MICVO showed a 36% response rate and 94% disease control in heavily pretreated head and neck cancer patients, with responses described as rapid, deep and durable and a manageable safety profile. The company said efficacy was consistent across key subgroups, supporting advancement to a global phase III trial.